History of HTN and an SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the Randomisation Visit.
At least one additional risk factor for HF:
* Age ≥ 70 years
* UACR \> 20 mg/g
* eGFR \< 60 mL/min/1.73 m2
* History of polyvascular disease (at least two of: ischaemic heart disease, cerebrovascular disease, and peripheral arterial disease)
* History of atrial fibrillation or atrial flutter
* NT-proBNP \> 125 ng/L
You may not be if
Previously confirmed diagnosis and treatment of heart failure
An eGFR \< 30 mL/min/1.73 m2 at screening
Known hyperkalaemia, defined as potassium ≥ 5.5 mmol/L within 3 months prior to screening
Type 1 diabetes mellitus or uncontrolled T2DM with HbA1c \> 10.5% (\> 91 mmol/mol) at screening
Serum sodium \< 135 mmol/L at screening, determined as per central laboratory assessment
Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, carotid angioplasty, or cardiac surgery, within 3 months prior to randomisation
Myocardial infarction within 3 months prior to randomisation, or within 1 month prior to randomisation when there is no further planned revascularisation
Percutaneous coronary intervention within 1 month prior to randomisation
Known severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history
Documented history of adrenal insufficiency
Any dialysis (including for acute kidney injury) within 3 months prior to screening
Any acute kidney injury within 3 months prior to screening
Prohibited concomitant medications
Clareo Health | Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
